Gossamer Bio Inc (GOSS) Stock Price, Quote & News

Company Profile

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to devel...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 684 1300

Website: www.gossamerbio.com

Address:

3115 Merryfield Row, Suite 120, San Diego, United States

MOOSEN Aug. 19 at 6:43 PM

$GOSS BEEN BOTTOM FEEDIN’.

0 · Reply

Bullishontherize Aug. 19 at 5:03 PM

$GOSS

0 · Reply

TheBeef79 Aug. 19 at 2:43 PM

$GOSS thx for the sector boost, MRNA lol

0 · Reply

BackdoorStocks9 Aug. 19 at 2:02 PM

$MRNA $GOSS is the easiest 10x play of all time.

0 · Reply

AlexRo777 Aug. 19 at 1:54 PM

$GOSS ridiculous gains

0 · Reply

Marc1283 Aug. 19 at 1:49 PM

$GOSS 🧨🚀

0 · Reply

Roaring_Capybara Aug. 19 at 9:15 AM

$GOSS $IMMP $CAPR @Coco63 IMMP is failed penny-stock garbage. Likely a short-worthy stock as its headed towards a reverse split. 🤣🤣🤣🤡🤡🤡

1 · Reply

Desmodromica Aug. 19 at 9:02 AM

$GOSS 8===D up up

0 · Reply

Coco63 Aug. 19 at 8:24 AM

$GOSS --> $IMMP is set to take off this weekend ahead of the pipeline update scheduled for next week. $CAPR is going to close the gap at $4, so in the meantime, go for IMMUTEP.

0 · Reply

Barry4408 Aug. 18 at 9:03 PM

$GOSS

0 · Reply

Gossamer Bio reports Q2 EPS (8c), consensus (12c)

2026-08-16T13:26:28.000Z - 3 days ago

Gossamer Bio price target lowered to $4 from $15 at Piper Sandler

Aug 13, 2026, 4:01 PM EDT - 5 days ago

Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update

Aug 13, 2026, 7:00 AM EDT - 6 days ago

Gossamer Bio Quarterly report: Q2 2026

Aug 13, 2026, 7:00 AM EDT - 6 days ago

Gossamer Bio Earnings release: Q2 2026

2026-07-27T22:00:09.000Z - 22 days ago

Gossamer Bio upgraded to Outperform from Market Perform at Leerink

Jul 27, 2026, 8:00 AM EDT - 23 days ago

Gossamer Bio Transcript: Investor update

Jul 27, 2026, 8:00 AM EDT - 23 days ago

Gossamer Bio Press release: Investor update

2026-07-27T11:10:56.000Z - 23 days ago

Gossamer announces FDA regulatory update, reacquisition of Seralutinib rights

Jul 27, 2026, 7:00 AM EDT - 23 days ago

Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update

2026-07-01T13:15:31.000Z - 7 weeks ago

Gossamer Bio announces determination of conversion rate for senior secured notes

Jul 1, 2026, 9:00 AM EDT - 7 weeks ago

Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants

2026-06-25T16:35:28.000Z - 7 weeks ago

Gossamer Bio price target lowered to $2 from $5 at H.C. Wainwright

2026-06-17T12:17:12.000Z - 2 months ago

Gossamer Bio announces final tender results

Jun 17, 2026, 8:00 AM EDT - 2 months ago

Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes

Jun 9, 2026, 8:00 AM EDT - 2 months ago

Gossamer Bio Proxy statement: Proxy filing

2026-06-03T13:13:56.000Z - 2 months ago

Gossamer Bio announces early tender results, early settlement of solicitation

Jun 3, 2026, 8:00 AM EDT - 2 months ago

Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes

2026-06-02T13:07:00.000Z - 2 months ago

Gossamer Bio announces extension of early tender date for exchange offer

Jun 2, 2026, 8:00 AM EDT - 2 months ago

Gossamer Bio, Inc. Announces Extension of Early Tender Date for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes

2026-05-29T09:38:46.000Z - 2 months ago

Investors Sue Gossamer Bio (GOSS) Over Inflated High Blood Pressure Study Claims

2026-05-20T20:11:13.000Z - 3 months ago